Basis: Unrounded diluted TTM EPS / FMP quote price × 100. Source: stored company filings and market data; unavailable inputs remain N/A.
The earnings yield is N/A as of 2026-10-06T15:42:39.899Z.
Calculation as of: 2026-10-06T15:42:39.899Z.
Quote observation: 2026-10-06T15:40:33.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 85bde4aa0a662304b106d2bd805683c4a4a85ed0eecab472c1d88190f6ac555e
EARNINGS YIELD
N/A
Market Cap
$1.46B
Earnings Yield
8.03%
TTM Avg
4.29%
3Y Avg
4.28%
5Y Avg
3.97%
Market Cap
$1.44B
Earnings Yield
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$1.51B
Earnings Yield
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$1.51B
Earnings Yield
6.53%
TTM Avg
5.17%
3Y Avg
3.51%
5Y Avg
4.79%
| NAME | MARKET CAP | EARNINGS YIELD | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Maze Therapeutics, Inc. (MAZE) | $1.47B | N/A | N/A | N/A | N/A |
| Braveheart Bio, Inc. (BRVE)vs › | $1.47B | N/A | N/A | N/A | N/A |
| Healthcare Services Group, Inc. (HCSG)vs › | $1.46B | 8.03% | 4.29% | 4.28% | 3.97% |
| Certara, Inc. (CERT)vs › | $1.49B | N/A | 0.64% | 0.61% | 0.61% |
| GH Research PLC (GHRS)vs › | $1.49B | N/A | N/A | N/A | N/A |
| Ultragenyx Pharmaceutical Inc. (RARE)vs › | $1.44B | N/A | N/A | N/A | N/A |
| AnaptysBio, Inc. (ANAB)vs › | $1.44B | 11.06% | 10.64% | 10.64% | 2.45% |
| Rapport Therapeutics, Inc. Common Stock (RAPP)vs › | $1.51B | N/A | N/A | N/A | N/A |
| Phibro Animal Health Corporation (PAHC)vs › | $1.51B | 6.53% | 5.17% | 3.51% | 4.79% |
| Kailera Therapeutics, Inc. (KLRA)vs › | $1.42B | N/A | N/A | N/A | N/A |
Earnings Yield
N/A
EPS ÷ Price
P/E Ratio
N/A
Price ÷ EPS
Formula: Earnings Yield = (EPS / Price) × 100
Earnings Yield is simply the inverse of P/E. A P/E of 20 equals a 5% earnings yield.
How earnings yield is used:
Earnings Yield = EPS (TTM) / Share Price
Earnings yield is the inverse of the PE ratio, expressing trailing earnings as a percentage of price. Higher is cheaper.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
